Physician profile
Krishna J Mohan
NPI 1477645786
$2,502.54
in general payments reported to CMS, 2019-2025
13 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $225 · 2021: $356 · 2022: $301 · 2023: $307 · 2024: $658 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,129.85 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,124.59 | 2020-2025 | Farxiga, Lokelma, Andexxa |
| Otsuka America Pharmaceutical, INC. | $222.06 | 2019-2020 | |
| Amgen INC. | $173.33 | 2022-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $151.02 | 2023-2024 | Jesduvroq, Benlysta |
| Paratek Pharmaceuticals, INC. | $125.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $121.15 | 2019 | |
| Novo Nordisk INC | $119.83 | 2025 | |
| Horizon Therapeutics Plc | $102.95 | 2019-2020 | |
| Akebia Therapeutics INC | $92.49 | 2019-2025 | Vafseo, Auryxia |
| Mallinckrodt Enterprises LLC | $74.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.98 | 2022-2024 | |
| Fresenius USA Marketing, INC. | $30.98 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.